Effect of Repeated Low-Level Red-Light Therapy on Retinal Function and Structure

Myopia Clinical Trial

Official title:

Effect of Repeated Low-Level Red-Light Therapy on Retinal Function and Structure Among Myopic Teenagers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05597397
• Other study ID #: RLS-SEPTC-2022
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2023
• Est. completion date: June 2023

Study information

• Verified date: April 2023
• Source: Shanghai Eye Disease Prevention and Treatment Center
• Contact: Xiangui He, PhD
• Phone: +862153555032
• Email: hxgcrco[@]shsyf.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to evaluate the effect of repeated low-level red-light (RLRL) therapy on the retinal function and structure among myopic teenagers.

Description:

Myopia constitutes a major threat to personal health globally for its increased prevalence. Moreover, its dose-related association with irreversible blindness complications such as myopic macular degeneration has been demonstrated. It is crucial to look for effective ways to control myopia in children to reduce risk of myopic pathologies in later life. Repeated low-level red-light (RLRL) therapy is an innovative and non-invasive therapeutic treatment for a variety of eye diseases. A previous randomized clinical trial suggested that RLRL could effectively controlled myopia progression without clinically observable side effects.

The purpose of this study is to evaluate the effect of RLRL on the retinal function and structure among myopic teenagers aged 15-16 years. The RLRL therapy will be carried out at school under supervision of the parents according to a standard protocol for the first month and then will be discontinued for 1 month. Detailed functional and structural examinations, including full field electroretinogram, multifocal electroretinogram, microperimetry, visual acuity, intraocular pressure, optical coherence tomography, optical coherence tomography angiography, cycloplegic spherical equivalent refraction, and biological parameters will be evaluated at 1 month, 2 months after enrollment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years to 16 Years

Eligibility

Inclusion Criteria:

1. Age: 15-16 years at enrolment.

2. Myopia: cycloplegic spherical equivalent refractions (SERs) range from -1.00 to -5.00 diopters (D) and astigmatism less than -2.5 D in either eye.

3. Best corrected visual acuity equal to or better than 0.8 in either eye.

4. Normal fundus, or tessellated fundus.

5. Provision of consent and able to participate in all required activities of the study.

Exclusion Criteria:

1. Secondary myopia, such as a history of retinopathy of prematurity or neonatal problems, or syndromic myopia with a known genetic disease or connective tissue disorders, such as Stickler or Marfan syndrome.

2. Strabismus and binocular vision abnormalities in either eye.

3. Refractive media opacity: corneal opacities, cataract, or implanted intraocular lens, etc.

4. Ocular abnormalities that affect retinal function: macular degeneration, diabetic retinopathy, retinal detachment, glaucoma, or ocular hypertension, endophthalmitis, uveitis, optic neuropathy, etc.

5. Previous history of refractive surgery, intraocular surgery, laser therapy, and intravitreal injection, etc.

6. Systemic abnormalities: diabetes, hypertension, etc.

7. Drugs therapies with toxicity effect on the retina: hydroxychloroquine, etc.

8. Prior treatment of myopia control in the past three months, drugs, orthokeratology, progressive addition lenses, bifocal lens, etc.

9. Other contraindications, including but not limited to ocular or other systemic abnormalities, that the physician may consider inappropriate for enrolment.

Related Conditions & MeSH terms

• Eye Diseases
• Myopia
• Refractive Errors
• Retina; Change

Intervention

Device:
• RLRL
In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.

Locations

Country	Name	City	State
China	Shanghai Eye Disease Prevention and Treatment Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Eye Disease Prevention and Treatment Center

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the amplitudes of waves.	Changes in the amplitudes are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by electroretinogram.	1 and 2 months
Primary	Changes in the latency of waves.	Changes in the latency of waves are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by electroretinogram.	1 and 2 months
Secondary	Changes in retinal sensitivity	Changes in retinal sensitivity are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by microperimetry.	1 and 2 months
Secondary	Changes in fixation stability	Changes in fixation stability are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by microperimetry.	1 and 2 months
Secondary	Changes in macular integrity	Changes in macular integrity are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by microperimetry.	1 and 2 months
Secondary	Changes in macular vessel density	Changes in macular vessel density are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by optical coherence tomography angiography.	1 and 2 months
Secondary	Changes in macular perfusion density	Changes in macular perfusion density are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by optical coherence tomography angiography.	1 and 2 months
Secondary	Changes in chorocapillaris flow defict percentage	Changes in choroidal vascularity index are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by optical coherence tomography angiography.	1 and 2 months
Secondary	Changes in choroidal vascularity index	Changes in choroidal vascularity index are characterized as the difference between each follow-up visit and corresponding baseline values which are measured by optical coherence tomography.	1 and 2 months
Secondary	Changes in best corrected visual acuity	Best corrected visual acuity changes are characterized as the difference between each follow up visit and baseline values. An Early Treatment Diabetic Retinopathy Study chart with standard illumination at a distance of 4 meters is used to measure best corrected visual acuity.	1 and 2 months